Bristol Myers Squibb (CELG-RI) Divestments (2009 - 2026)

Bristol Myers Squibb has disclosed Divestments across 18 years of filings, most recently posting $312.0 million for Q1 2026.

• In Q1 2026, Divestments rose 28.4% year-over-year to $312.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 3.54% YoY), while the FY2025 annual figure was $1.1 billion, down 2.55% from the prior year.
• Divestments rose to $312.0 million in Q1 2026, from $279.0 million in the prior quarter.
• Over the last five years, Divestments for CELG-RI reached as high as $490.0 million in Q4 2022 and fell as low as $192.0 million in Q2 2022.
• The 5-year median for Divestments is $255.0 million (2024), against an average of $276.2 million.
• Annual changes were most pronounced in 2022 — Divestments soared 175.28% — and 2023, when it slumped 50.82%.
• A 5-year view of Divestments shows it stood at $490.0 million in 2022, then tumbled by 50.82% to $241.0 million in 2023, then jumped by 38.17% to $333.0 million in 2024, then dropped by 16.22% to $279.0 million in 2025, then grew by 11.83% to $312.0 million in 2026.
• According to Business Quant data, Divestments over the past three periods registered $312.0 million, $279.0 million, and $279.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.